Treatment of HIV infection with raltegravir
Authors:
- Lisa M ChirchLCLisa M Chirch
- Sidonie MorrisonSMSidonie Morrison
- Roy T SteigbigelRSRoy T Steigbigel
- 22 April 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (7) , 1203-1211
Abstract
(2009). Treatment of HIV infection with raltegravir. Expert Opinion on Pharmacotherapy: Vol. 10, No. 7, pp. 1203-1211. doi: 10.1517/14656560902911488Keywords
This publication has 16 references indexed in Scilit:
- Estimation of HIV Incidence in the United StatesJAMA, 2008
- The aftermath of the Merck's HIV vaccine trialRetrovirology, 2008
- HIV‐1 Integrase Inhibitors: Update and Perspectives2008
- Inhibition of Human Immunodeficiency Virus Type 1 Concerted Integration by Strand Transfer Inhibitors Which Recognize a Transient Structural IntermediateJournal of Virology, 2007
- In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediateRetrovirology, 2007
- CD4+ Count–Guided Interruption of Antiretroviral TreatmentNew England Journal of Medicine, 2006
- Structure and Function of HIV-1 IntegraseCurrent Topics in Medicinal Chemistry, 2004
- HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integraseProceedings of the National Academy of Sciences, 2000
- Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in CellsScience, 2000
- Crystal Structure of the Catalytic Domain of HIV-1 Integrase: Similarity to Other Polynucleotidyl TransferasesScience, 1994